IDRA-21

IDRA-21

200px
Systematic (IUPAC) name
7-chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide
Legal status
Legal status	Investigational New Medicine
Identifiers
CAS Number	22503-72-6
PubChem	CID 3688
Synonyms	IDRA-21
Chemical data
Formula	C8H9ClN2O2S
Molar mass	232.68726 g/mol[[]]

IDRA-21 is an ampakine drug derived from aniracetam. IDRA-21 is a chiral molecule, with (+)-IDRA-21 being the active form.

IDRA-21 shows nootropic effects in animal studies, significantly improving learning and memory. It is around 10-30x more potent than aniracetam in reversing cognitive deficits induced by alprazolam or scopolamine, and produces sustained effects lasting for up to three days after a single dose. The mechanism for this action is thought to be through promoting the induction of long-term potentiation between synapses in the brain.

IDRA-21 does not produce neurotoxicity under normal conditions, although it may worsen neuronal damage following global ischemia after stroke or seizures.

In comparison to the benzoylpiperidine derived ampakine drugs, IDRA-21 was more potent than CX-516, but less potent than CX-546. Newer benzothiadiazide derivatives with greatly increased potency compared to IDRA-21 have been developed, but these have not been researched to the same extent, with the benzoylpiperidine and benzoylpyrrolidine CX- series of drugs being favoured for clinical development, most likely due to more favourable toxicity profiles at high doses.

See also

• S-18986